We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CLVLY market cap is 510.8M. The company's latest EPS is AUD 0.6105 and P/E is 25.47.
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 31.05M | 32.69M | 48.11M | 65.94M | 78.35M |
| Operating Income | 16.69M | 10.33M | 26.83M | 33.27M | 40.93M |
| Net Income | 18.13M | 15.05M | 24.73M | 20.88M | 30.61M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 62.35M | 81.54M | 108.57M | 143.95M | 193.71M |
| Total Liabilities | 5.17M | 9.48M | 9.83M | 18.39M | 29.08M |
| Total Equity | 57.18M | 72.07M | 98.74M | 125.56M | 164.63M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | 18.46M | 14.19M | 19.26M | 39.87M | 36.91M |
| Investing | -258k | -888k | -854k | -434k | -1.03M |
| Financing | -1.03M | -1.49M | -1.48M | -1.5M | -2.24M |
| Market Cap | 510.8M |
| Price to Earnings Ratio | 25.47 |
| Price to Sales Ratio | 9.95 |
| Price to Cash Ratio | 4.97 |
| Price to Book Ratio | 4.73 |
| Dividend Yield | 0.28% |
| Shares Outstanding | 50.13M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.41 (3.94%) |
| Company Name | Clinuvel Pharmaceuticals Ltd (PK) |
| Address |
level 11 melbourne, victoria 3000 |
| Website | https://www.clinuvel.com |
| Industry | drugs-health r&d/testing labs (H8) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
